相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom
Richa Sinha et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis
Yougen Wu et al.
HEMATOLOGY (2017)
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
Gustaaf W. van Imhoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells
Sladjana Skopelja-Gardner et al.
JOURNAL OF IMMUNOLOGY (2017)
Which Anti-CD20 Antibody Is Better in Follicular Lymphoma?
James O. Armitage et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era Prevention and Management
Eamonn S. Molloy et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2017)
Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy
Ana Teresa Paquete et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2017)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies
Rut Valgardsdottir et al.
BLOOD (2017)
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
Guillaume Cartron et al.
HAEMATOLOGICA (2016)
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
Guillaume Cartron et al.
HAEMATOLOGICA (2016)
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation
Kazumi Hayashi et al.
CANCER SCIENCE (2016)
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system
Dennis W. Raisch et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands
Hedwig M. Blommestein et al.
LEUKEMIA RESEARCH (2016)
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy
Ursula Becker et al.
VALUE IN HEALTH (2016)
Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12
H. S. Walter et al.
BLOOD CANCER JOURNAL (2016)
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
Luis Felipe Casado et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2016)
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
Ciara L. Freeman et al.
BLOOD (2015)
Obinutuzumab in hematologic malignancies: Lessons learned to date
Tim Illidge et al.
CANCER TREATMENT REVIEWS (2015)
Tumor-associated macrophages in diffuse large B-cell lymphoma
Robert Kridel et al.
HAEMATOLOGICA (2015)
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen et al.
LANCET (2015)
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
V. Goede et al.
LEUKEMIA (2015)
Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
L. Ysebaert et al.
BLOOD CANCER JOURNAL (2015)
Tumor-associated macrophages in diffuse large B-cell lymphoma
Robert Kridel et al.
HAEMATOLOGICA (2015)
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
Ronald P. Taylor et al.
BLOOD (2015)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Sari Riihijarvi et al.
HAEMATOLOGICA (2015)
Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro
Jennifer D. Koenitzer et al.
PLOS ONE (2015)
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL
N. Murawski et al.
ANNALS OF ONCOLOGY (2014)
Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
Michael Pfreundschuh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity
Grzegorz Terszowski et al.
JOURNAL OF IMMUNOLOGY (2014)
New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor
Tim M. Illidge et al.
LEUKEMIA & LYMPHOMA (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
Juan Du et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
Josee Golay et al.
BLOOD (2013)
At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity
Anne Danielou-Lazareth et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
Gilles A. Salles et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
Sarwish Rafiq et al.
JOURNAL OF IMMUNOLOGY (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia
Emilie Laprevotte et al.
LEUKEMIA RESEARCH (2013)
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Christian Klein et al.
MABS (2013)
Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
Jamie Honeychurch et al.
BLOOD (2012)
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Gilles Salles et al.
BLOOD (2012)
Aphase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
Laurie H. Sehn et al.
BLOOD (2012)
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
Carsten Mueller et al.
BLOOD (2012)
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
Masahiko Mihara et al.
CLINICAL SCIENCE (2012)
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
Ulrich Jaeger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
Jing Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Frank J. Beurskens et al.
JOURNAL OF IMMUNOLOGY (2012)
Fc-Gamma-Receptor IIIa Polymorphism and Gene Expression Profile Do Not Predict the Prognosis in Diffuse Large B-cell Lymphoma Treated with R-CHOP Protocol
Laszlo Varoczy et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
Rituximab resistance
Andrew R. Rezvani et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
Gerhard Niederfellner et al.
BLOOD (2011)
Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
Madhavi Challa-Malladi et al.
CANCER CELL (2011)
Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
Guillaume Cartron et al.
CLINICAL CANCER RESEARCH (2011)
rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
Xiaowen Ge et al.
CLINICAL CANCER RESEARCH (2011)
The predictive significance of CD20 expression in B-cell lymphomas
Veronika Kloboves Prevodnik et al.
DIAGNOSTIC PATHOLOGY (2011)
Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia
Wei Xu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Analysis of CD16(+)CD56(dim) NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
M. Le Garff-Tavernier et al.
LEUKEMIA (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
Marinus H. J. van Oers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study
Joseph J. Sacco et al.
PLOS ONE (2010)
Antigenic Modulation and Rituximab Resistance
Ronald P. Taylor et al.
SEMINARS IN HEMATOLOGY (2010)
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Junji Hiraga et al.
BLOOD (2009)
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
Nathalie A. Johnson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Acquired resistance to rituximeb is associated with chemotherapy resistance resulting from decreased Bax and Bak expression
Scott H. Olejniczak et al.
CLINICAL CANCER RESEARCH (2008)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling
Claire A. Walshe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
M. Pfreundschuh et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
Liat Binyamin et al.
JOURNAL OF IMMUNOLOGY (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphorna patients regardless of their response to induction chemotherapy
Wen-Kai Weng et al.
BLOOD (2007)
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia
Michael E. Williams et al.
JOURNAL OF IMMUNOLOGY (2006)
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Dong Hwan Kim et al.
BLOOD (2006)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
K Takei et al.
LEUKEMIA RESEARCH (2006)
The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
PV Beum et al.
JOURNAL OF IMMUNOLOGY (2006)
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells
JA Bowles et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders
LN Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg et al.
BLOOD (2004)
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia
AD Kennedy et al.
JOURNAL OF IMMUNOLOGY (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance
R Bannerji et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The mechanisms of action of rituximab in the elimination of tumor cells
P Johnson et al.
SEMINARS IN ONCOLOGY (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
Rituximab dose-escalation trial in chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
